Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University136 enrolled

Overview

The goal of this observational study is to explore the application of temporal diffusion spectroscopy MRI in head and neck squamous cell carcinoma (HNSCC). The main questions it aims to answer are: * If the quantitative parameters of temporal diffusion spectroscopy MRI can predict the comprehensive positive score (CPS) of pathological PD-L1 expression in HNSCC? * If the quantitative parameters of temporal diffusion spectroscopy MRI can predict the efficacy of neoadjuvant therapy in HNSCC? Participants will receive head and neck MRI, including T2WI, T1WI, diffusion-weighted imaging (DWI), oscillating gradient spin echo (OGSE) and pulsed gradient spin echo (PGSE) sequence before and after neoadjuvant therapy. There is not a comparison group in our study.

Study Type

OBSERVATIONAL

Enrollment

136

Conditions

Head and Neck Squamous Cell Carcinoma Magnetic Resonance Imaging Neoadjuvant Therapy

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients first diagnosed with head and neck squamous cell carcinoma (HNSCC) by pathological biopsy * Patients proposed to receive 2-3 courses of neoadjuvant chemotherapy and immunotherapy * Patients without contraindications for MRI, such as nonremovable ferromagnetic metal foreign body, claustrophobia, renal insufficiency, and previous history of gadolinium contrast allergy Exclusion Criteria: * Less than 10mm in the maximum diameter of the baseline primary tumor * Poor MRI image quality with obvious metal or motion artifacts * The failure to complete the course of neoadjuvant therapy

Outcomes

Primary Outcomes

Comprehensive positive score

Comprehensive positive score for PD-L1 expression

Time frame: 1 week before neoadjuvant therapy

Pathological response

Postoperative pathological tumor residual status

Time frame: 1 month after the last neoadjuvant therapy

Change from maximum transverse tumor diameter after neoadjuvant therapy

Maximum transverse tumor diameter before and after neoadjuvant therapy

Time frame: 1 week before the first neoadjuvant therapy and 1 month after the last neoadjuvant therapy